Robeco Institutional Asset Management B.V. Sells 4,094 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Robeco Institutional Asset Management B.V. trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 2.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 191,925 shares of the biotechnology company’s stock after selling 4,094 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in United Therapeutics were worth $67,719,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in UTHR. USA Financial Formulas bought a new position in shares of United Therapeutics in the third quarter worth about $33,000. Brooklyn Investment Group bought a new position in United Therapeutics in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in United Therapeutics during the 3rd quarter worth $82,000. MassMutual Private Wealth & Trust FSB boosted its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on UTHR shares. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $378.36.

United Therapeutics Stock Performance

Shares of UTHR opened at $372.75 on Thursday. The firm has a market capitalization of $16.64 billion, a PE ratio of 16.37, a P/E/G ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The stock has a 50 day simple moving average of $365.77 and a 200 day simple moving average of $356.81.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.38 EPS. Equities research analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $919,164.36. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 149,048 shares of company stock worth $56,142,199. 11.90% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.